1 Report Overview 1.1 Research Scope 1.2 Market Segment by Type 1.2.1 Global Chronic Obstructive Pulmonary Disease Drugs Market Size Growth Rate by Type (2017 VS 2021 VS 2028) 1.2.2 Inhalers 1.2.3 Nebulizers 1.3 Market Segment by Application 1.3.1 Global Chronic Obstructive Pulmonary Disease Drugs Market Share by Application (2017 VS 2021 VS 2028) 1.3.2 Emphysema 1.3.3 Chronic Bronchitis 1.3.4 Refractory Asthma 1.3.5 Others 1.4 Study Objectives 1.5 Years Considered 2 Market Perspective 2.1 Global Chronic Obstructive Pulmonary Disease Drugs Market Size (2017-2028) 2.1.1 Global Chronic Obstructive Pulmonary Disease Drugs Revenue (2017-2028) 2.1.2 Global Chronic Obstructive Pulmonary Disease Drugs Sales (2017-2028) 2.2 Global Chronic Obstructive Pulmonary Disease Drugs Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028 2.2.1 Global Chronic Obstructive Pulmonary Disease Drugs Sales by Regions (2017-2022) 2.2.2 Global Chronic Obstructive Pulmonary Disease Drugs Revenue by Regions (2017-2022) 2.3 Global Chronic Obstructive Pulmonary Disease Drugs Market Size Forecast by Region 2.3.1 Global Chronic Obstructive Pulmonary Disease Drugs Sales Forecast by Region (2023-2028) 2.3.2 Global Chronic Obstructive Pulmonary Disease Drugs Revenue Forecast by Region (2023-2028) 2.4 Global Top Chronic Obstructive Pulmonary Disease Drugs Regions (Countries) Ranking by Market Size 2.5 Chronic Obstructive Pulmonary Disease Drugs Market Dynamics 2.5.1 Chronic Obstructive Pulmonary Disease Drugs Market Trends 2.5.2 Chronic Obstructive Pulmonary Disease Drugs Market Drivers 2.5.3 Chronic Obstructive Pulmonary Disease Drugs Market Challenges 2.5.4 Chronic Obstructive Pulmonary Disease Drugs Market Restraints 3 Competitive Landscape by Manufacturers 3.1 Global Top Chronic Obstructive Pulmonary Disease Drugs Manufacturers by Sales (2017-2022) 3.1.1 Global Chronic Obstructive Pulmonary Disease Drugs Sales by Manufacturers (2017-2022) 3.1.2 Global Chronic Obstructive Pulmonary Disease Drugs Sales Market Share by Manufacturers (2017-2022) 3.1.3 Global 5 and 10 Largest Manufacturers by Chronic Obstructive Pulmonary Disease Drugs Sales in 2021 3.2 Global Top Manufacturers Chronic Obstructive Pulmonary Disease Drugs by Revenue 3.2.1 Global Chronic Obstructive Pulmonary Disease Drugs Revenue by Manufacturers (2017-2022) 3.2.2 Top Chronic Obstructive Pulmonary Disease Drugs Manufacturers Covered: Ranking by Revenue 3.2.3 Global Chronic Obstructive Pulmonary Disease Drugs Revenue Share by Manufacturers (2017-2022) 3.2.4 Global Chronic Obstructive Pulmonary Disease Drugs Market Concentration Ratio (CR5 and HHI) 3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Chronic Obstructive Pulmonary Disease Drugs as of 2021) 3.4 Global Chronic Obstructive Pulmonary Disease Drugs Average Selling Price (ASP) by Manufacturers 3.5 Key Manufacturers Chronic Obstructive Pulmonary Disease Drugs Plants/Factories Distribution and Area Served 3.6 Date of Key Manufacturers Enter into Chronic Obstructive Pulmonary Disease Drugs Market 3.7 Key Manufacturers Chronic Obstructive Pulmonary Disease Drugs Product Offered 3.8 Mergers & Acquisitions, Expansion Plans 4 Global Chronic Obstructive Pulmonary Disease Drugs Market Size by Type 4.1 Global Chronic Obstructive Pulmonary Disease Drugs Historic Market Review by Type (2017-2022) 4.1.1 Global Chronic Obstructive Pulmonary Disease Drugs Sales Market Share by Type (2017-2022) 4.1.2 Global Chronic Obstructive Pulmonary Disease Drugs Revenue Market Share by Type (2017-2022) 4.1.3 Chronic Obstructive Pulmonary Disease Drugs Price by Type (2017-2022) 4.2 Global Chronic Obstructive Pulmonary Disease Drugs Market Estimates and Forecasts by Type (2023-2028) 4.2.1 Global Chronic Obstructive Pulmonary Disease Drugs Sales Forecast by Type (2023-2028) 4.2.2 Global Chronic Obstructive Pulmonary Disease Drugs Revenue Forecast by Type (2023-2028) 4.2.3 Chronic Obstructive Pulmonary Disease Drugs Price Forecast by Type (2023-2028) 5 Global Chronic Obstructive Pulmonary Disease Drugs Market Size by Application 5.1 Global Chronic Obstructive Pulmonary Disease Drugs Historic Market Review by Application (2017-2022) 5.1.1 Global Chronic Obstructive Pulmonary Disease Drugs Sales Market Share by Application (2017-2022) 5.1.2 Global Chronic Obstructive Pulmonary Disease Drugs Revenue Market Share by Application (2017-2022) 5.1.3 Chronic Obstructive Pulmonary Disease Drugs Price by Application (2017-2022) 5.2 Global Chronic Obstructive Pulmonary Disease Drugs Market Estimates and Forecasts by Application (2023-2028) 5.2.1 Global Chronic Obstructive Pulmonary Disease Drugs Sales Forecast by Application (2023-2028) 5.2.2 Global Chronic Obstructive Pulmonary Disease Drugs Revenue Forecast by Application (2023-2028) 5.2.3 Chronic Obstructive Pulmonary Disease Drugs Price Forecast by Application (2023-2028) 6 North America 6.1 North America Chronic Obstructive Pulmonary Disease Drugs Sales Breakdown by Company 6.1.1 North America Chronic Obstructive Pulmonary Disease Drugs Sales by Company (2017-2022) 6.1.2 North America Chronic Obstructive Pulmonary Disease Drugs Revenue by Company (2017-2022) 6.2 North America Chronic Obstructive Pulmonary Disease Drugs Market Size by Type 6.2.1 North America Chronic Obstructive Pulmonary Disease Drugs Sales by Type (2017-2028) 6.2.2 North America Chronic Obstructive Pulmonary Disease Drugs Revenue by Type (2017-2028) 6.3 North America Chronic Obstructive Pulmonary Disease Drugs Market Size by Application 6.3.1 North America Chronic Obstructive Pulmonary Disease Drugs Sales by Application (2017-2028) 6.3.2 North America Chronic Obstructive Pulmonary Disease Drugs Revenue by Application (2017-2028) 6.4 North America Chronic Obstructive Pulmonary Disease Drugs Market Size by Country 6.4.1 North America Chronic Obstructive Pulmonary Disease Drugs Sales by Country (2017-2028) 6.4.2 North America Chronic Obstructive Pulmonary Disease Drugs Revenue by Country (2017-2028) 6.4.3 United States 6.4.4 Canada 6.4.5 Mexico 7 Europe 7.1 Europe Chronic Obstructive Pulmonary Disease Drugs Sales Breakdown by Company 7.1.1 Europe Chronic Obstructive Pulmonary Disease Drugs Sales by Company (2017-2022) 7.1.2 Europe Chronic Obstructive Pulmonary Disease Drugs Revenue by Company (2017-2022) 7.2 Europe Chronic Obstructive Pulmonary Disease Drugs Market Size by Type 7.2.1 Europe Chronic Obstructive Pulmonary Disease Drugs Sales by Type (2017-2028) 7.2.2 Europe Chronic Obstructive Pulmonary Disease Drugs Revenue by Type (2017-2028) 7.3 Europe Chronic Obstructive Pulmonary Disease Drugs Market Size by Application 7.3.1 Europe Chronic Obstructive Pulmonary Disease Drugs Sales by Application (2017-2028) 7.3.2 Europe Chronic Obstructive Pulmonary Disease Drugs Revenue by Application (2017-2028) 7.4 Europe Chronic Obstructive Pulmonary Disease Drugs Market Size by Country 7.4.1 Europe Chronic Obstructive Pulmonary Disease Drugs Sales by Country (2017-2028) 7.4.2 Europe Chronic Obstructive Pulmonary Disease Drugs Revenue by Country (2017-2028) 7.4.3 Germany 7.4.4 France 7.4.5 UK 7.4.6 Italy 7.4.7 Russia 8 Asia Pacific 8.1 Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Sales Breakdown by Company 8.1.1 Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Sales by Company (2017-2022) 8.1.2 Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Revenue by Company (2017-2022) 8.2 Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Market Size by Type 8.2.1 Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Sales by Type (2017-2028) 8.2.2 Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Revenue by Type (2017-2028) 8.3 Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Market Size by Application 8.3.1 Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Sales by Application (2017-2028) 8.3.2 Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Revenue by Application (2017-2028) 8.4 Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Market Size by Region 8.4.1 Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Sales by Region 8.4.2 Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Revenue by Region 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 India 8.4.7 Australia 8.4.8 Indonesia 8.4.9 Thailand 8.4.10 Malaysia 8.4.11 Philippines 8.4.12 Vietnam 9 Latin America 9.1 Latin America Chronic Obstructive Pulmonary Disease Drugs Sales Breakdown by Company 9.1.1 Latin America Chronic Obstructive Pulmonary Disease Drugs Sales by Company (2017-2022) 9.1.2 Latin America Chronic Obstructive Pulmonary Disease Drugs Revenue by Company (2017-2022) 9.2 Latin America Chronic Obstructive Pulmonary Disease Drugs Market Size by Type 9.2.1 Latin America Chronic Obstructive Pulmonary Disease Drugs Sales by Type (2017-2028) 9.2.2 Latin America Chronic Obstructive Pulmonary Disease Drugs Revenue by Type (2017-2028) 9.3 Latin America Chronic Obstructive Pulmonary Disease Drugs Market Size by Application 9.3.1 Latin America Chronic Obstructive Pulmonary Disease Drugs Sales by Application (2017-2028) 9.3.2 Latin America Chronic Obstructive Pulmonary Disease Drugs Revenue by Application (2017-2028) 9.4 Latin America Chronic Obstructive Pulmonary Disease Drugs Market Size by Country 9.4.1 Latin America Chronic Obstructive Pulmonary Disease Drugs Sales by Country (2017-2028) 9.4.2 Latin America Chronic Obstructive Pulmonary Disease Drugs Revenue by Country (2017-2028) 9.4.3 Mexico 9.4.4 Brazil 9.4.5 Argentina 10 Middle East and Africa 10.1 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Sales Breakdown by Company 10.1.1 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Sales by Company (2017-2022) 10.1.2 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Revenue by Company (2017-2022) 10.2 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Market Size by Type 10.2.1 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Sales by Type (2017-2028) 10.2.2 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Revenue by Type (2017-2028) 10.3 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Market Size by Application 10.3.1 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Sales by Application (2017-2028) 10.3.2 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Revenue by Application (2017-2028) 10.4 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Market Size by Country 10.4.1 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Sales by Country (2017-2028) 10.4.2 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Revenue by Country (2017-2028) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Company Profiles 11.1 AstraZeneca 11.1.1 AstraZeneca Corporation Information 11.1.2 AstraZeneca Overview 11.1.3 AstraZeneca Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.1.4 AstraZeneca Chronic Obstructive Pulmonary Disease Drugs Products and Services 11.1.5 AstraZeneca Chronic Obstructive Pulmonary Disease Drugs SWOT Analysis 11.1.6 AstraZeneca Recent Developments 11.2 Boehringer Ingelheim 11.2.1 Boehringer Ingelheim Corporation Information 11.2.2 Boehringer Ingelheim Overview 11.2.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.2.4 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Drugs Products and Services 11.2.5 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Drugs SWOT Analysis 11.2.6 Boehringer Ingelheim Recent Developments 11.3 GSK 11.3.1 GSK Corporation Information 11.3.2 GSK Overview 11.3.3 GSK Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.3.4 GSK Chronic Obstructive Pulmonary Disease Drugs Products and Services 11.3.5 GSK Chronic Obstructive Pulmonary Disease Drugs SWOT Analysis 11.3.6 GSK Recent Developments 11.4 Novartis 11.4.1 Novartis Corporation Information 11.4.2 Novartis Overview 11.4.3 Novartis Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.4.4 Novartis Chronic Obstructive Pulmonary Disease Drugs Products and Services 11.4.5 Novartis Chronic Obstructive Pulmonary Disease Drugs SWOT Analysis 11.4.6 Novartis Recent Developments 11.5 Teva Pharmaceuticals 11.5.1 Teva Pharmaceuticals Corporation Information 11.5.2 Teva Pharmaceuticals Overview 11.5.3 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.5.4 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Products and Services 11.5.5 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs SWOT Analysis 11.5.6 Teva Pharmaceuticals Recent Developments 11.6 Ache Laboratorios Farmaceuticos 11.6.1 Ache Laboratorios Farmaceuticos Corporation Information 11.6.2 Ache Laboratorios Farmaceuticos Overview 11.6.3 Ache Laboratorios Farmaceuticos Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.6.4 Ache Laboratorios Farmaceuticos Chronic Obstructive Pulmonary Disease Drugs Products and Services 11.6.5 Ache Laboratorios Farmaceuticos Chronic Obstructive Pulmonary Disease Drugs SWOT Analysis 11.6.6 Ache Laboratorios Farmaceuticos Recent Developments 11.7 Almirall 11.7.1 Almirall Corporation Information 11.7.2 Almirall Overview 11.7.3 Almirall Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.7.4 Almirall Chronic Obstructive Pulmonary Disease Drugs Products and Services 11.7.5 Almirall Chronic Obstructive Pulmonary Disease Drugs SWOT Analysis 11.7.6 Almirall Recent Developments 11.8 Aquinox Pharmaceuticals 11.8.1 Aquinox Pharmaceuticals Corporation Information 11.8.2 Aquinox Pharmaceuticals Overview 11.8.3 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.8.4 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Products and Services 11.8.5 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs SWOT Analysis 11.8.6 Aquinox Pharmaceuticals Recent Developments 11.9 Ario Pharma 11.9.1 Ario Pharma Corporation Information 11.9.2 Ario Pharma Overview 11.9.3 Ario Pharma Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.9.4 Ario Pharma Chronic Obstructive Pulmonary Disease Drugs Products and Services 11.9.5 Ario Pharma Chronic Obstructive Pulmonary Disease Drugs SWOT Analysis 11.9.6 Ario Pharma Recent Developments 11.10 Asmacure 11.10.1 Asmacure Corporation Information 11.10.2 Asmacure Overview 11.10.3 Asmacure Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.10.4 Asmacure Chronic Obstructive Pulmonary Disease Drugs Products and Services 11.10.5 Asmacure Chronic Obstructive Pulmonary Disease Drugs SWOT Analysis 11.10.6 Asmacure Recent Developments 11.11 Astellas Pharma 11.11.1 Astellas Pharma Corporation Information 11.11.2 Astellas Pharma Overview 11.11.3 Astellas Pharma Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.11.4 Astellas Pharma Chronic Obstructive Pulmonary Disease Drugs Products and Services 11.11.5 Astellas Pharma Recent Developments 11.12 BioMarck Pharmaceuticals 11.12.1 BioMarck Pharmaceuticals Corporation Information 11.12.2 BioMarck Pharmaceuticals Overview 11.12.3 BioMarck Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.12.4 BioMarck Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Products and Services 11.12.5 BioMarck Pharmaceuticals Recent Developments 12 Value Chain and Sales Channels Analysis 12.1 Chronic Obstructive Pulmonary Disease Drugs Value Chain Analysis 12.2 Chronic Obstructive Pulmonary Disease Drugs Key Raw Materials 12.2.1 Key Raw Materials 12.2.2 Raw Materials Key Suppliers 12.3 Chronic Obstructive Pulmonary Disease Drugs Production Mode & Process 12.4 Chronic Obstructive Pulmonary Disease Drugs Sales and Marketing 12.4.1 Chronic Obstructive Pulmonary Disease Drugs Sales Channels 12.4.2 Chronic Obstructive Pulmonary Disease Drugs Distributors 12.5 Chronic Obstructive Pulmonary Disease Drugs Customers 13 Research Findings and Conclusion 14 Appendix 14.1 Research Methodology 14.1.1 Methodology/Research Approach 14.1.2 Data Source 14.2 Author Details 14.3 Disclaimer

List of Tables Table 1. Global Chronic Obstructive Pulmonary Disease Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million) Table 2. Major Manufacturers of Inhalers Table 3. Major Manufacturers of Nebulizers Table 4. Global Chronic Obstructive Pulmonary Disease Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million) Table 5. Global Chronic Obstructive Pulmonary Disease Drugs Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028 Table 6. Global Chronic Obstructive Pulmonary Disease Drugs Sales by Region (2017-2022) & (K Units) Table 7. Global Chronic Obstructive Pulmonary Disease Drugs Sales Market Share by Region (2017-2022) Table 8. Global Chronic Obstructive Pulmonary Disease Drugs Revenue by Region (2017-2022) & (US$ Million) Table 9. Global Chronic Obstructive Pulmonary Disease Drugs Revenue Market Share by Region (2017-2022) Table 10. Global Chronic Obstructive Pulmonary Disease Drugs Sales Forecast by Region (2023-2028) & (K Units) Table 11. Global Chronic Obstructive Pulmonary Disease Drugs Sales Market Share Forecast by Region (2023-2028) Table 12. Global Chronic Obstructive Pulmonary Disease Drugs Revenue Forecast by Region (2023-2028) & (US$ Million) Table 13. Global Chronic Obstructive Pulmonary Disease Drugs Revenue Market Share Forecast by Region (2023-2028) Table 14. Top Chronic Obstructive Pulmonary Disease Drugs Regions (Countries) Ranking by Market Size (US$ Million) in 2021 Table 15. Chronic Obstructive Pulmonary Disease Drugs Market Trends Table 16. Chronic Obstructive Pulmonary Disease Drugs Market Drivers Table 17. Chronic Obstructive Pulmonary Disease Drugs Market Challenges Table 18. Chronic Obstructive Pulmonary Disease Drugs Market Restraints Table 19. Global Chronic Obstructive Pulmonary Disease Drugs Sales by Manufacturers (2017-2022) & (K Units) Table 20. Global Chronic Obstructive Pulmonary Disease Drugs Sales Share by Manufacturers (2017-2022) Table 21. Global Chronic Obstructive Pulmonary Disease Drugs Revenue by Manufacturers (2017-2022) & (US$ Million) Table 22. Ranking of Global Top Chronic Obstructive Pulmonary Disease Drugs Manufacturers by Revenue (US$ Million) in 2021 Table 23. Chronic Obstructive Pulmonary Disease Drugs Revenue Share by Manufacturers (2017-2022) Table 24. Global Chronic Obstructive Pulmonary Disease Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) Table 25. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Chronic Obstructive Pulmonary Disease Drugs as of 2021) Table 26. Key Manufacturers Chronic Obstructive Pulmonary Disease Drugs Average Selling Price (ASP) & (2017-2022) & (USD/Unit) Table 27. Key Manufacturers Chronic Obstructive Pulmonary Disease Drugs Plants/Factories Distribution Table 28. Key Manufacturers Chronic Obstructive Pulmonary Disease Drugs Area Served Table 29. Date of Key Manufacturers Enter into Chronic Obstructive Pulmonary Disease Drugs Market Table 30. Key Manufacturers Chronic Obstructive Pulmonary Disease Drugs Product Type Table 31. Mergers & Acquisitions, Expansion Plans Table 32. Global Chronic Obstructive Pulmonary Disease Drugs Sales (K Units) by Type (2017-2022) Table 33. Global Chronic Obstructive Pulmonary Disease Drugs Sales Share by Type (2017-2022) Table 34. Global Chronic Obstructive Pulmonary Disease Drugs Revenue (US$ Million) Market Share by Type (2017-2022) Table 35. Global Chronic Obstructive Pulmonary Disease Drugs Price (K Units) by Type (2017-2022) Table 36. Global Chronic Obstructive Pulmonary Disease Drugs Sales (K Units) by Type (2023-2028) Table 37. Global Chronic Obstructive Pulmonary Disease Drugs Sales Share by Type (2023-2028) Table 38. Global Chronic Obstructive Pulmonary Disease Drugs Revenue (US$ Million) Market Share by Type (2023-2028) Table 39. Global Chronic Obstructive Pulmonary Disease Drugs Revenue Share by Type (2023-2028) Table 40. Global Chronic Obstructive Pulmonary Disease Drugs Price (K Units) by Type (2023-2028) Table 41. Global Chronic Obstructive Pulmonary Disease Drugs Sales (K Units) by Application (2017-2022) Table 42. Global Chronic Obstructive Pulmonary Disease Drugs Sales Share by Application (2017-2022) Table 43. Global Chronic Obstructive Pulmonary Disease Drugs Revenue (US$ Million) Market Share by Application (2017-2022) Table 44. Global Chronic Obstructive Pulmonary Disease Drugs Price (K Units) by Application (2017-2022) Table 45. Global Chronic Obstructive Pulmonary Disease Drugs Sales (K Units) by Application (2023-2028) Table 46. Global Chronic Obstructive Pulmonary Disease Drugs Sales Share by Application (2023-2028) Table 47. Global Chronic Obstructive Pulmonary Disease Drugs Revenue (US$ Million) Market Share by Application (2023-2028) Table 48. Global Chronic Obstructive Pulmonary Disease Drugs Revenue Share by Application (2023-2028) Table 49. Global Chronic Obstructive Pulmonary Disease Drugs Price (K Units) by Application (2023-2028) Table 50. North America Chronic Obstructive Pulmonary Disease Drugs Sales by Company (2017-2022) & (K Units) Table 51. North America Chronic Obstructive Pulmonary Disease Drugs Sales Market Share by Company (2017-2022) Table 52. North America Chronic Obstructive Pulmonary Disease Drugs Revenue by Company (2017-2022) & (US$ Million) Table 53. North America Chronic Obstructive Pulmonary Disease Drugs Revenue Market Share by Company (2017-2022) Table 54. North America Chronic Obstructive Pulmonary Disease Drugs Sales by Type (2017-2022) & (K Units) Table 55. North America Chronic Obstructive Pulmonary Disease Drugs Sales by Type (2023-2028) & (K Units) Table 56. North America Chronic Obstructive Pulmonary Disease Drugs Revenue by Type (2017-2022) & (US$ Million) Table 57. North America Chronic Obstructive Pulmonary Disease Drugs Revenue by Type (2023-2028) & (US$ Million) Table 58. North America Chronic Obstructive Pulmonary Disease Drugs Sales by Application (2017-2022) & (K Units) Table 59. North America Chronic Obstructive Pulmonary Disease Drugs Sales by Application (2023-2028) & (K Units) Table 60. North America Chronic Obstructive Pulmonary Disease Drugs Revenue by Application (2017-2022) & (US$ Million) Table 61. North America Chronic Obstructive Pulmonary Disease Drugs Revenue by Application (2023-2028) & (US$ Million) Table 62. North America Chronic Obstructive Pulmonary Disease Drugs Sales by Country (2017-2022) & (K Units) Table 63. North America Chronic Obstructive Pulmonary Disease Drugs Sales by Country (2023-2028) & (K Units) Table 64. North America Chronic Obstructive Pulmonary Disease Drugs Revenue by Country (2017-2022) & (US$ Million) Table 65. North America Chronic Obstructive Pulmonary Disease Drugs Revenue by Country (2023-2028) & (US$ Million) Table 66. Europe Chronic Obstructive Pulmonary Disease Drugs Sales by Company (2017-2022) & (K Units) Table 67. Europe Chronic Obstructive Pulmonary Disease Drugs Sales Market Share by Company (2017-2022) Table 68. Europe Chronic Obstructive Pulmonary Disease Drugs Revenue by Company (2017-2022) & (US$ Million) Table 69. Europe Chronic Obstructive Pulmonary Disease Drugs Revenue Market Share by Company (2017-2022) Table 70. Europe Chronic Obstructive Pulmonary Disease Drugs Sales by Type (2017-2022) & (K Units) Table 71. Europe Chronic Obstructive Pulmonary Disease Drugs Sales by Type (2023-2028) & (K Units) Table 72. Europe Chronic Obstructive Pulmonary Disease Drugs Revenue by Type (2017-2022) & (US$ Million) Table 73. Europe Chronic Obstructive Pulmonary Disease Drugs Revenue by Type (2023-2028) & (US$ Million) Table 74. Europe Chronic Obstructive Pulmonary Disease Drugs Sales by Application (2017-2022) & (K Units) Table 75. Europe Chronic Obstructive Pulmonary Disease Drugs Sales by Application (2023-2028) & (K Units) Table 76. Europe Chronic Obstructive Pulmonary Disease Drugs Revenue by Application (2017-2022) & (US$ Million) Table 77. Europe Chronic Obstructive Pulmonary Disease Drugs Revenue by Application (2023-2028) & (US$ Million) Table 78. Europe Chronic Obstructive Pulmonary Disease Drugs Sales by Country (2017-2022) & (K Units) Table 79. Europe Chronic Obstructive Pulmonary Disease Drugs Sales by Country (2023-2028) & (K Units) Table 80. Europe Chronic Obstructive Pulmonary Disease Drugs Revenue by Country (2017-2022) & (US$ Million) Table 81. Europe Chronic Obstructive Pulmonary Disease Drugs Revenue by Country (2023-2028) & (US$ Million) Table 82. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Sales by Company (2017-2022) & (K Units) Table 83. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Sales Market Share by Company (2017-2022) Table 84. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Revenue by Company (2017-2022) & (US$ Million) Table 85. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Revenue Market Share by Company (2017-2022) Table 86. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Sales by Type (2017-2022) & (K Units) Table 87. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Sales by Type (2023-2028) & (K Units) Table 88. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Revenue by Type (2017-2022) & (US$ Million) Table 89. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Revenue by Type (2023-2028) & (US$ Million) Table 90. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Sales by Application (2017-2022) & (K Units) Table 91. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Sales by Application (2023-2028) & (K Units) Table 92. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Revenue by Application (2017-2022) & (US$ Million) Table 93. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Revenue by Application (2023-2028) & (US$ Million) Table 94. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Sales by Region (2017-2022) & (K Units) Table 95. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Sales by Region (2023-2028) & (K Units) Table 96. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Revenue by Region (2017-2022) & (US$ Million) Table 97. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Revenue by Region (2023-2028) & (US$ Million) Table 98. Latin America Chronic Obstructive Pulmonary Disease Drugs Sales by Company (2017-2022) & (K Units) Table 99. Latin America Chronic Obstructive Pulmonary Disease Drugs Sales Market Share by Company (2017-2022) Table 100. Latin America Chronic Obstructive Pulmonary Disease Drugs Revenue by Company (2017-2022) & (US$ Million) Table 101. Latin America Chronic Obstructive Pulmonary Disease Drugs Revenue Market Share by Company (2017-2022) Table 102. Latin America Chronic Obstructive Pulmonary Disease Drugs Sales by Type (2017-2022) & (K Units) Table 103. Latin America Chronic Obstructive Pulmonary Disease Drugs Sales by Type (2023-2028) & (K Units) Table 104. Latin America Chronic Obstructive Pulmonary Disease Drugs Revenue by Type (2017-2022) & (US$ Million) Table 105. Latin America Chronic Obstructive Pulmonary Disease Drugs Revenue by Type (2023-2028) & (US$ Million) Table 106. Latin America Chronic Obstructive Pulmonary Disease Drugs Sales by Application (2017-2022) & (K Units) Table 107. Latin America Chronic Obstructive Pulmonary Disease Drugs Sales by Application (2023-2028) & (K Units) Table 108. Latin America Chronic Obstructive Pulmonary Disease Drugs Revenue by Application (2017-2022) & (US$ Million) Table 109. Latin America Chronic Obstructive Pulmonary Disease Drugs Revenue by Application (2023-2028) & (US$ Million) Table 110. Latin America Chronic Obstructive Pulmonary Disease Drugs Sales by Country (2017-2022) & (K Units) Table 111. Latin America Chronic Obstructive Pulmonary Disease Drugs Sales by Country (2023-2028) & (K Units) Table 112. Latin America Chronic Obstructive Pulmonary Disease Drugs Revenue by Country (2017-2022) & (US$ Million) Table 113. Latin America Chronic Obstructive Pulmonary Disease Drugs Revenue by Country (2023-2028) & (US$ Million) Table 114. Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Sales by Company (2017-2022) & (K Units) Table 115. Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Sales Market Share by Company (2017-2022) Table 116. Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Revenue by Company (2017-2022) & (US$ Million) Table 117. Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Revenue Market Share by Company (2017-2022) Table 118. Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Sales by Type (2017-2022) & (K Units) Table 119. Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Sales by Type (2023-2028) & (K Units) Table 120. Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Revenue by Type (2017-2022) & (US$ Million) Table 121. Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Revenue by Type (2023-2028) & (US$ Million) Table 122. Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Sales by Application (2017-2022) & (K Units) Table 123. Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Sales by Application (2023-2028) & (K Units) Table 124. Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Revenue by Application (2017-2022) & (US$ Million) Table 125. Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Revenue by Application (2023-2028) & (US$ Million) Table 126. Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Sales by Country (2017-2022) & (K Units) Table 127. Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Sales by Country (2023-2028) & (K Units) Table 128. Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Revenue by Country (2017-2022) & (US$ Million) Table 129. Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Revenue by Country (2023-2028) & (US$ Million) Table 130. AstraZeneca Corporation Information Table 131. AstraZeneca Description and Overview Table 132. AstraZeneca Chronic Obstructive Pulmonary Disease Drugs Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 133. AstraZeneca Chronic Obstructive Pulmonary Disease Drugs Product and Services Table 134. AstraZeneca Chronic Obstructive Pulmonary Disease Drugs SWOT Analysis Table 135. AstraZeneca Recent Developments Table 136. Boehringer Ingelheim Corporation Information Table 137. Boehringer Ingelheim Description and Overview Table 138. Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Drugs Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 139. Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Drugs Product and Services Table 140. Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Drugs SWOT Analysis Table 141. Boehringer Ingelheim Recent Developments Table 142. GSK Corporation Information Table 143. GSK Description and Overview Table 144. GSK Chronic Obstructive Pulmonary Disease Drugs Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 145. GSK Chronic Obstructive Pulmonary Disease Drugs Product and Services Table 146. GSK Chronic Obstructive Pulmonary Disease Drugs SWOT Analysis Table 147. GSK Recent Developments Table 148. Novartis Corporation Information Table 149. Novartis Description and Overview Table 150. Novartis Chronic Obstructive Pulmonary Disease Drugs Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 151. Novartis Chronic Obstructive Pulmonary Disease Drugs Product and Services Table 152. Novartis Chronic Obstructive Pulmonary Disease Drugs SWOT Analysis Table 153. Novartis Recent Developments Table 154. Teva Pharmaceuticals Corporation Information Table 155. Teva Pharmaceuticals Description and Overview Table 156. Teva Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 157. Teva Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Product and Services Table 158. Teva Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs SWOT Analysis Table 159. Teva Pharmaceuticals Recent Developments Table 160. Ache Laboratorios Farmaceuticos Corporation Information Table 161. Ache Laboratorios Farmaceuticos Description and Overview Table 162. Ache Laboratorios Farmaceuticos Chronic Obstructive Pulmonary Disease Drugs Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 163. Ache Laboratorios Farmaceuticos Chronic Obstructive Pulmonary Disease Drugs Product and Services Table 164. Ache Laboratorios Farmaceuticos Chronic Obstructive Pulmonary Disease Drugs SWOT Analysis Table 165. Ache Laboratorios Farmaceuticos Recent Developments Table 166. Almirall Corporation Information Table 167. Almirall Description and Overview Table 168. Almirall Chronic Obstructive Pulmonary Disease Drugs Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 169. Almirall Chronic Obstructive Pulmonary Disease Drugs Product and Services Table 170. Almirall Chronic Obstructive Pulmonary Disease Drugs SWOT Analysis Table 171. Almirall Recent Developments Table 172. Aquinox Pharmaceuticals Corporation Information Table 173. Aquinox Pharmaceuticals Description and Overview Table 174. Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 175. Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Product and Services Table 176. Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs SWOT Analysis Table 177. Aquinox Pharmaceuticals Recent Developments Table 178. Ario Pharma Corporation Information Table 179. Ario Pharma Description and Overview Table 180. Ario Pharma Chronic Obstructive Pulmonary Disease Drugs Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 181. Ario Pharma Chronic Obstructive Pulmonary Disease Drugs Product and Services Table 182. Ario Pharma Chronic Obstructive Pulmonary Disease Drugs SWOT Analysis Table 183. Ario Pharma Recent Developments Table 184. Asmacure Corporation Information Table 185. Asmacure Description and Overview Table 186. Asmacure Chronic Obstructive Pulmonary Disease Drugs Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 187. Asmacure Chronic Obstructive Pulmonary Disease Drugs Product and Services Table 188. Asmacure Chronic Obstructive Pulmonary Disease Drugs SWOT Analysis Table 189. Asmacure Recent Developments Table 190. Astellas Pharma Corporation Information Table 191. Astellas Pharma Description and Overview Table 192. Astellas Pharma Chronic Obstructive Pulmonary Disease Drugs Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 193. Astellas Pharma Chronic Obstructive Pulmonary Disease Drugs Product and Services Table 194. Astellas Pharma Recent Developments Table 195. BioMarck Pharmaceuticals Corporation Information Table 196. BioMarck Pharmaceuticals Description and Overview Table 197. BioMarck Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 198. BioMarck Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Product and Services Table 199. BioMarck Pharmaceuticals Recent Developments Table 200. Key Raw Materials Lists Table 201. Raw Materials Key Suppliers Lists Table 202. Chronic Obstructive Pulmonary Disease Drugs Distributors List Table 203. Chronic Obstructive Pulmonary Disease Drugs Customers List Table 204. Research Programs/Design for This Report Table 205. Key Data Information from Secondary Sources Table 206. Key Data Information from Primary Sources List of Figures Figure 1. Chronic Obstructive Pulmonary Disease Drugs Product Picture Figure 2. Global Chronic Obstructive Pulmonary Disease Drugs Sales Market Share by Type in 2021 & 2028 Figure 3. Inhalers Product Picture Figure 4. Nebulizers Product Picture Figure 5. Global Chronic Obstructive Pulmonary Disease Drugs Sales Market Share by Application in 2021 & 2028 Figure 6. Emphysema Use Case Figure 7. Chronic Bronchitis Use Case Figure 8. Refractory Asthma Use Case Figure 9. Others Use Case Figure 10. Chronic Obstructive Pulmonary Disease Drugs Report Years Considered Figure 11. Global Chronic Obstructive Pulmonary Disease Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028 Figure 12. Global Chronic Obstructive Pulmonary Disease Drugs Market Size 2017-2028 (US$ Million) Figure 13. Global Chronic Obstructive Pulmonary Disease Drugs Sales (2017-2022) & (K Units) Figure 14. Global Chronic Obstructive Pulmonary Disease Drugs Market Size Market Share by Region: 2021 VS 2028 Figure 15. Global Chronic Obstructive Pulmonary Disease Drugs Sales Market Share by Region (2017-2022) Figure 16. Global Chronic Obstructive Pulmonary Disease Drugs Sales Market Share by Region in 2021 Figure 17. Global Chronic Obstructive Pulmonary Disease Drugs Revenue Market Share by Region in 2017 VS 2021 Figure 18. Global Chronic Obstructive Pulmonary Disease Drugs Sales Share by Manufacturers in 2021 Figure 19. The 5 and 10 Largest Manufacturers in the World: Market Share by Chronic Obstructive Pulmonary Disease Drugs Sales in 2021 Figure 20. Chronic Obstructive Pulmonary Disease Drugs Revenue Share by Manufacturers in 2021 Figure 21. Chronic Obstructive Pulmonary Disease Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021 Figure 22. Global Chronic Obstructive Pulmonary Disease Drugs Revenue Share by Type (2017-2022) Figure 23. Global Chronic Obstructive Pulmonary Disease Drugs Revenue Growth Rate by Type in 2017 & 2021 Figure 24. Global Chronic Obstructive Pulmonary Disease Drugs Revenue Share by Application (2017-2022) Figure 25. Global Chronic Obstructive Pulmonary Disease Drugs Revenue Growth Rate by Application in 2017 & 2021 Figure 26. North America Chronic Obstructive Pulmonary Disease Drugs Sales Market Share by Type (2017-2028) Figure 27. North America Chronic Obstructive Pulmonary Disease Drugs Revenue Market Share by Type (2017-2028) Figure 28. North America Chronic Obstructive Pulmonary Disease Drugs Sales Market Share by Application (2017-2028) Figure 29. North America Chronic Obstructive Pulmonary Disease Drugs Revenue Market Share by Application (2017-2028) Figure 30. North America Chronic Obstructive Pulmonary Disease Drugs Sales Share by Country (2017-2028) Figure 31. North America Chronic Obstructive Pulmonary Disease Drugs Revenue Share by Country (2017-2028) Figure 32. United States Chronic Obstructive Pulmonary Disease Drugs Revenue (2017-2028) & (US$ Million) Figure 33. Canada Chronic Obstructive Pulmonary Disease Drugs Revenue (2017-2028) & (US$ Million) Figure 34. Mexico Chronic Obstructive Pulmonary Disease Drugs Revenue (2017-2028) & (US$ Million) Figure 35. Europe Chronic Obstructive Pulmonary Disease Drugs Sales Market Share by Type (2017-2028) Figure 36. Europe Chronic Obstructive Pulmonary Disease Drugs Revenue Market Share by Type (2017-2028) Figure 37. Europe Chronic Obstructive Pulmonary Disease Drugs Sales Market Share by Application (2017-2028) Figure 38. Europe Chronic Obstructive Pulmonary Disease Drugs Revenue Market Share by Application (2017-2028) Figure 39. Europe Chronic Obstructive Pulmonary Disease Drugs Sales Share by Country (2017-2028) Figure 40. Europe Chronic Obstructive Pulmonary Disease Drugs Revenue Share by Country (2017-2028) Figure 41. Germany Chronic Obstructive Pulmonary Disease Drugs Revenue (2017-2028) & (US$ Million) Figure 42. France Chronic Obstructive Pulmonary Disease Drugs Revenue (2017-2028) & (US$ Million) Figure 43. UK Chronic Obstructive Pulmonary Disease Drugs Revenue (2017-2028) & (US$ Million) Figure 44. Italy Chronic Obstructive Pulmonary Disease Drugs Revenue (2017-2028) & (US$ Million) Figure 45. Russia Chronic Obstructive Pulmonary Disease Drugs Revenue (2017-2028) & (US$ Million) Figure 46. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Sales Market Share by Type (2017-2028) Figure 47. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Revenue Market Share by Type (2017-2028) Figure 48. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Sales Market Share by Application (2017-2028) Figure 49. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Revenue Market Share by Application (2017-2028) Figure 50. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Sales Share by Region (2017-2028) Figure 51. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Revenue Share by Region (2017-2028) Figure 52. China Chronic Obstructive Pulmonary Disease Drugs Revenue (2017-2028) & (US$ Million) Figure 53. Japan Chronic Obstructive Pulmonary Disease Drugs Revenue (2017-2028) & (US$ Million) Figure 54. South Korea Chronic Obstructive Pulmonary Disease Drugs Revenue (2017-2028) & (US$ Million) Figure 55. India Chronic Obstructive Pulmonary Disease Drugs Revenue (2017-2028) & (US$ Million) Figure 56. Australia Chronic Obstructive Pulmonary Disease Drugs Revenue (2017-2028) & (US$ Million) Figure 57. Indonesia Chronic Obstructive Pulmonary Disease Drugs Revenue (2017-2028) & (US$ Million) Figure 58. Thailand Chronic Obstructive Pulmonary Disease Drugs Revenue (2017-2028) & (US$ Million) Figure 59. Malaysia Chronic Obstructive Pulmonary Disease Drugs Revenue (2017-2028) & (US$ Million) Figure 60. Philippines Chronic Obstructive Pulmonary Disease Drugs Revenue (2017-2028) & (US$ Million) Figure 61. Vietnam Chronic Obstructive Pulmonary Disease Drugs Revenue (2017-2028) & (US$ Million) Figure 62. Latin America Chronic Obstructive Pulmonary Disease Drugs Sales Market Share by Type (2017-2028) Figure 63. Latin America Chronic Obstructive Pulmonary Disease Drugs Revenue Market Share by Type (2017-2028) Figure 64. Latin America Chronic Obstructive Pulmonary Disease Drugs Sales Market Share by Application (2017-2028) Figure 65. Latin America Chronic Obstructive Pulmonary Disease Drugs Revenue Market Share by Application (2017-2028) Figure 66. Latin America Chronic Obstructive Pulmonary Disease Drugs Sales Share by Country (2017-2028) Figure 67. Latin America Chronic Obstructive Pulmonary Disease Drugs Revenue Share by Country (2017-2028) Figure 68. Mexico Chronic Obstructive Pulmonary Disease Drugs Revenue (2017-2028) & (US$ Million) Figure 69. Brazil Chronic Obstructive Pulmonary Disease Drugs Revenue (2017-2028) & (US$ Million) Figure 70. Argentina Chronic Obstructive Pulmonary Disease Drugs Revenue (2017-2028) & (US$ Million) Figure 71. Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Sales Market Share by Type (2017-2028) Figure 72. Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Revenue Market Share by Type (2017-2028) Figure 73. Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Sales Market Share by Application (2017-2028) Figure 74. Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Revenue Market Share by Application (2017-2028) Figure 75. Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Sales Share by Country (2017-2028) Figure 76. Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Revenue Share by Country (2017-2028) Figure 77. Turkey Chronic Obstructive Pulmonary Disease Drugs Revenue (2017-2028) & (US$ Million) Figure 78. Saudi Arabia Chronic Obstructive Pulmonary Disease Drugs Revenue (2017-2028) & (US$ Million) Figure 79. UAE Chronic Obstructive Pulmonary Disease Drugs Revenue (2017-2028) & (US$ Million) Figure 80. Chronic Obstructive Pulmonary Disease Drugs Value Chain Figure 81. Chronic Obstructive Pulmonary Disease Drugs Production Process Figure 82. Channels of Distribution Figure 83. Distributors Profiles Figure 84. Bottom-up and Top-down Approaches for This Report Figure 85. Data Triangulation Figure 86. Key Executives Interviewed

AstraZeneca Boehringer Ingelheim GSK Novartis Teva Pharmaceuticals Ache Laboratorios Farmaceuticos Almirall Aquinox Pharmaceuticals Ario Pharma Asmacure Astellas Pharma BioMarck Pharmaceuticals